Abstract: The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus.

Abstract: The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus.

Abstract: The present invention provides a timed pulse release composition comprising: a. a core composition comprising a therapeutically active agent, a swelling agent, and optionally water soluble compound(s) for inducing osmosis, and b. a coat composition comprising one or more film forming polymers, wherein upon imbibing fluid from the surrounding the core swells, and the coat ruptures to release in a pulse, the therapeutically active agent in a reliable manner at about a predetermined time wherein the reliable manner of rupture comprises rupturing of 36 tablets out of a total of 36 tablets at about the predetermined time when tested by subjecting the tablets to USP dissolution test using an aqueous media at 37±0.5oC, in a USP Type I or Type II apparatus at an rpm selected from the range of about 50 rpm to about 100 rpm.

Abstract: The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus.

Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Abstract: The invention relates to a novel advantageous oral dosage form for methanediphosphonates, especially the active ingredient disodium pamidronate. A preferred dosage form comprises:a) disodium-3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate),b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate,c) further pharmaceutically acceptable excipients.The ingredients can be processed to form tablets, dragees, capsules etc.

Abstract: An inhaler for introducing a metered amount of solids, for example pharmaceutically active powders, into a stream of air drawn in by a user comprises a storage chamber into which a metering rod extends. The metering rod is provided with a metering recess which fixes the amount of solids to be mixed with the air stream. The storage chamber and the metering rod are movable relative to each other in such a manner that in a first relative position of the metering rod and the storage chamber the metering recess of the metering rod is located in the storage chamber, where it is filled with solids, and in a second relative position it is located in the air channel, where the solids are mixed with the air stream. The axial relative movement can be brought about by the rotation of two housing parts over sloping surfaces.

Abstract: A vibratory conveyor for forming flowable grain agglomerations from previously poorly flowable fine-grained powder and thereafter conveying said agglomerations to a metering chamber which comprises a mechanical vibration device to agglomerate the poorly flowable powder, transport means for conveying the agglomerated powder and metering means for collecting and measuring the conveyed powder; and a method directed thereto wherein the poorly flowable powder is subjected to a mechanical vibration step prior to transport and metering.

Abstract: The present invention relates to improved oral forms of administration, for example syrups, having a delayed release characteristic, of carbamazepine. The delayed release of carbamazepine is achieved by the manufacture of an advantageous cubic crystal form of suitable size of dihydrate crystals contained in the form of administration.

Abstract: The invention relates to a pharmaceutical composition for the application of baclofen, in the form of an adhesive tablet, to the mucosa in the oral cavity, which pharmaceutical composition comprisesa) a hydrophilic tablet core, the top surface of which adheres to the receptor surface of the oral mucosa and which contains the drug baclofen or a pharmaceutically acceptable salt thereof and, as excipients, a swellable vinyl polymer, a galactomannan and/or a pharmaceutically acceptable wax and/or a glyceride or completely or partially hydrogenated glyceride, and further optional excipients, and if, desired,b) a hydrophobic coating which covers the tablet core a), with the exception of the surface provided for the release of baclofen.The invention further relates to a process for the preparation of this adhesive tablet and the therepeutic use thereof as spasmolytic.

Abstract: The present invention relates to a therapeutic system with systemic action for peroral administration, having a compartment for active ingredients, which system contains in that compartment sparingly soluble active ingredients, swelling agents and, optionally, water-soluble substances for producing an osmotic pressure.

Abstract: The invention relates to a therapeutic system for peroral administration and having systemic action, which system is in the form of a coated and/or laminated monocompartment system for administering carbamazepine. The therapeutic system comprises(a) a wall made of a material which is permeable to water and impermeable to the components of the drug-containing core,(b) a core containing finely particulate carbamazepine as drug and, as auxiliaries, a protective colloid that inhibits the crystal growth of carbamazepine in the presence of water, a swellable hydrophilic polymer and, optionally, a water-soluble compound for inducing osmosis and/or further pharmaceutically acceptable excipients, and(c) a passageway through the wall (a) for delivering the core components to the environmental body fluid. The therapeutic system can be used as an anticonvulsive for the treatment of convulsive states, especially epileptic states.

Abstract: Solid, stable dosage forms consisting of a moisture- and temperature-sensitive core prepared from a medicament, or a mixture of medicaments, and excipients, and an elastic film coating which decomposes in aqueous solution, said elastic film coating substantially comprising(a) a water-soluble component consisting of20-60% of hydroxypropyl cellulose having an average molecular weight of 75,000, and(b) a water-insoluble component consisting of5-20% of an acrylic resin in the form of(b.sub.1) a 70:30 ethyl acrylate/methyl methacrylate copolymer having a molecular weight of 80,000, or(b.sub.2) a 30:70 to 70:30 methyl acrylate/methyl methacrylate copolymer having an average molecular weight of 500,000,20-60% of a lubricant,0.5-5% of a wetting agent,0-5% of a plasticizer,and optional additional excipients, and process for the preparation thereof.

Abstract: A pharmaceutical preparation for controlled, sustained release of dextromethorphan comprising a polystyrene sulfonate resin which has been cross-linked with about 3% to about 10% divinyl benzene, having an average particle size of at least 48 .mu.m and less than 100 .mu.m onto which dextromethorphan has been loaded in a ratio of dextromethorphan hydrobromid to resin of about 1:3 to about 1:10 and at least one pharmaceutically acceptable adjuvant.

Abstract: A resinate of the formula ##STR1## wherein Am.sup..sym. is a strongly basic copolymer of styrene and divinylbenzene which is in cationic form, said copolymer containing the sum of m+n quaternary ammonium groups and also containing, as main structural unit, the grouping of the formula ##STR2## X.sup..crclbar. is the anion of an acid different from the anion of the formula ##STR3## and m and n denote the entire ion capacity of the copolymer, and the molecular weight of which is about 10.sup.7 to 10.sup.9, a process for the preparation of said resinate, the use thereof as active ingredient of a drug, and pharmaceutical compositions containing it.

Abstract: The invention relates to a process for the manufacture of prolonged action and stable vincamine preparations, which process comprises reacting an acid addition salt of vincamine with an alkali metal salt or alkaline earth metal salt of a sulfonic acid cation exchange resin, in particular an alkali metal salt of a sulfonated copolymer of styrene with a small amount of divinyl benzene, in a polar reaction medium such as water. The invention further relates to the vincamine preparations so obtained, to the use thereof for the manufacture of ready-for-use medicaments for oral administration and to these medicaments themselves.

Abstract: The invention relates to a therapeutic system for peroral administration and having systemic action, which system is in the form of a coated and/or laminated mono-compartment system for administering carbamazepine. The therapeutic system comprises(a) a wall made of a material which is permeable to water and impermeable to the components of the drug-containing core,(b) a core containing finely particulate carbamazepine as drug and, as auxiliaries, a protective colloid that inhibits the crystal growth of carbamazepine in the presence of water, a swellable hydrophilic polymer and, optionally, a water-soluble compound for inducing osmosis and/or further pharmaceutically acceptable excipients, and(c) a passageway through the wall (a) for delivering the core components to the environmental body fluid. The therapeutic system can be used as an anticonvulsive for the treatment of convulsive states, especially epileptic states.